Evidence map›Paper›PMID 30673934›Full record

ArticleClinical and experimental nephrology2019

Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.

Tetsuhiro Tanaka, Masaomi Nangaku, Enyu Imai, Yoshiharu Tsubakihara, Masatoshi Kamai, Michihito Wada, Shinji Asada, Tadao Akizawa

Abstract readPublished Erratum
In one paragraph

Article in Clinical and experimental nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Tetsuhiro TanakaDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
Enyu ImaiInternal Medicine of Nakayamadera Imai Clinic, Takarazuka, Hyogo, Japan.
Yoshiharu TsubakiharaGraduate School of Health Care Sciences, Jikei Institute, Yodogawa-ku, Osaka, Japan.
Masatoshi KamaiPharmacovigilance Department, Kyowa Hakko Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan.
Michihito WadaMedical Affairs Department, Kyowa Hakko Kirin Co., Ltd., Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan.
Shinji AsadaMedical Affairs Department, Kyowa Hakko Kirin Co., Ltd., Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan. shinji.asada@kyowa-kirin.co.jp.
Tadao AkizawaShowa University, Shinagawa-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the original publication of the article, two sentences in the "Results" section were published incorrectly. The corrected texts are provided below.

Identifiers

PMID30673934
PMCPMC6828206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.